




SUNDAY 8 SEPTEMBER 2019	
7:00	Industry Symposia 07:00 - 08:00
08:00	Late Breaking Industry Abstracts and Selected Poster Presentations 08:00 - 10:00 Chair: S. Ashina (USA)
	<p>08:00 - 08:10 - IHC-OR-038- Acute Treatment Patterns Among New Triptan Treatment Users and Potential Triptan-Insufficient Responders (H. Viswanathan, USA)</p> <p>08:10- 08:20 - IHC-OR-039-Sustained efficacy and long-term safety of erenumab in patients with episodic migraine: 4+ year results of a 5-year, open-label treatment period (A.Nair,USA)</p> <p>08:20-08:30 - IHC-OR-040-Efficacy and safety of fremanezumab for the prevention of episodic cluster headache: results of a randomized, double-blind, placebo-controlled, phase 3 study (J.Cohen,USA)</p> <p>08:30 - 08:40 - IHC-OR-041- Acute Treatment with Rimegepant 75mg Confers Clinically Relevant Improvement in Migraine-Related Disability: Results from a One Year, Open-Label Safety Study (BHV3000-201) (G.Litalien, USA)</p> <p>08:40 - 08:50 - IHC-OR-042- A Randomized, Placebo-Controlled Study of Galcanezumab in Patients with Treatment-Resistant Migraine: Double-Blind Results from the CONQUER Study (W. Mulleners, The Netherlands)</p> <p>08:50 - 09:00 - IHC-OR-043- Long-term Safety of Qtrypta for the Acute Treatment of Migraine – 1-year Safety Results of Nearly 6,000 Treated Attacks (S.Nahas, USA)</p> <p>09:00 - 10:00 - Six winning posters (two voted for by the Juniors Group and four from delegate votes) will be presented</p>
	Exhibition Open 08:00 - 11:30
10:00	Coffee break 10:00-10:15
10:15	Awards and Closing Ceremony 10:15-10:45
10:45	

Colour Key



Sessions

- Teaching Courses
- Plenary Sessions
- Parallel Sessions
- Industry Symposia
- Exhibition
- AGM
- Oral Communications
- Cephalalgia Award Lecture / Awards and Closing Ceremor
- Coffee break / Lunch / Poster Walk
- Social Activities